Acumen Pharmaceuticals

Halozyme announces FDA approval for Roche's Tecentriq Hybreza™, a subcutaneous anti-PD-(L)1 immunotherapy using ENHANZE® technology, offering faster administration and broader treatment options for lung, liver, skin, and soft tissue cancers.

FDA approves Roche's Tecentriq Hybreza™, a subcutaneous anti-PD-(L)1 immunotherapy using Halozyme's ENHANZE® technology, reducing injection time to 7 minutes from 30-60 minutes for IV infusion, available for adult indications of IV Tecentriq® in the U.S.

Expert in IP strategy for FDA-approved drugs and clinical trials, with significant M&A experience in pharma. Represented numerous companies and investors in financings, IPOs, and IP diligence. Co-creator of healthcare investment initiatives and board member at LaunchBio.

Halozyme Therapeutics reported strong Q4 and full-year 2023 results, with a 26% revenue increase to $829M and a 24% rise in royalty revenue to $448M. The company highlighted growth from its ENHANZE technology and commercial products, projecting 2024 revenue between $915M and $985M. Key achievements include advancements in subcutaneous drug delivery and partnerships, with a focus on expanding its pipeline and leveraging its high-volume auto-injector technology.